CARsgen Reports Promising Early Results for Allogeneic BCMA CAR-T Therapy in Relapsed Primary Plasma Cell Leukemia
CARsgen Therapeutics Holdings Ltd. has reported promising early results for its allogeneic BCMA-targeted CAR-T therapy, CT0596, in treating relapsed primary plasma cell leukemia (pPCL). Preliminary data from two enrolled patients showed both achieved stringent complete response post-infusion, with robust CAR-T cell expansion and manageable safety profiles. Adverse events included cytokine release syndrome and hematologic toxicities, but no significant organ toxicities were noted. These findings support further investigation of CT0596 in plasma cell neoplasms.
CARsgen Therapeutics Holdings Ltd. has announced preliminary clinical data for its allogeneic BCMA-targeted CAR-T therapy, CT0596, developed using the THANK-u Plus™ platform. The therapy is currently being evaluated in investigator-initiated trials for the treatment of primary plasma cell leukemia (pPCL), a rare and aggressive plasma cell malignancy with limited treatment options. As of October 17, 2025, two patients with relapsed or refractory pPCL had been enrolled. Both patients achieved stringent complete response following CT0596 infusion, with robust CAR-T cell expansion and manageable safety profiles. Adverse events included cytokine release syndrome and hematologic toxicities, but no significant organ toxicities were observed. These results have already been presented and support continued investigation of CT0596 in plasma cell neoplasms. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01459) on October 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
